Welcome to our dedicated page for Masimo Corporation news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo Corporation stock.
Masimo Corporation (NASDAQ: MASI) is a leading global medical technology company specializing in the development and manufacturing of innovative noninvasive patient monitoring technologies. For over 27 years, Masimo has been at the forefront of medical advancements, offering a wide array of sensors and devices that enhance patient care and safety. Their products are designed to provide healthcare professionals with critical information to improve clinical decision-making.
Masimo's core business is divided into two segments: healthcare and non-healthcare. The healthcare segment is the primary revenue generator, focusing on noninvasive patient monitoring technologies, hospital automation, connectivity solutions, and remote monitoring devices. Their clinically proven products are widely used in hospitals, emergency rooms, and clinical settings around the world.
The non-healthcare segment encompasses the consumer audio business, which includes the development, manufacturing, marketing, and licensing of premium and luxury audio sound products. This segment is known for its advanced audio integration technologies that appeal to audiophiles and general consumers alike.
Masimo's recent achievements include expanding their product portfolio with advanced remote monitoring solutions, partnering with leading healthcare organizations, and pioneering innovative technologies that address unsolvable medical challenges. Financially, the company is robust, showing consistent growth and a strong market presence.
Masimo’s dedication to improving lives is evident in their mission to save, extend, and enhance the quality of life across all demographics. Their innovative spirit attracts individuals who are passionate about making a significant impact in the medical field. As they continue to innovate, Masimo remains committed to providing top-tier products that meet the evolving needs of the healthcare industry.
Masimo (NASDAQ: MASI) revealed findings from a study presented at Euroanaesthesia 2020, led by Dr. Kumagai at Iwate Medical University. The research demonstrated that Masimo ORi™, or Oxygen Reserve Index, effectively limits postoperative hyperoxia, potentially preventing hypoxia. In a trial involving 50 breast surgery patients, those monitored with ORi had significantly lower arterial oxygen levels post-surgery compared to a control group. However, ORi is currently not available in the U.S. due to the lack of FDA 510(k) clearance.
Masimo (NASDAQ: MASI) presented findings at Euroanaesthesia 2020, revealing that its noninvasive hemoglobin monitoring technology, SpHb, significantly improved outcomes in pediatric patients undergoing major surgeries. The study indicated a reduced rate of postoperative transfusions, shorter ICU stays, and decreased morbidity compared to traditional methods. Key metrics showed a 40% reduction in ICU stay durations and a 43% decrease in postoperative red blood cell transfusions. These results highlight SpHb's potential for better patient care and cost-effectiveness in transfusion management.
Masimo (NASDAQ: MASI) was recognized as one of seven innovators at California Life Sciences Association's Pantheon 2020 for its role in addressing COVID-19 challenges. The company's Masimo SafetyNet platform supports remote patient monitoring, enabling clinicians to track patients' health metrics from home, thus alleviating hospital strain. Mike Guerra from CLSA praised Masimo's adaptability during the pandemic. CEO Joe Kiani acknowledged the frontline healthcare workers' contributions and highlighted the impact of their technology in improving patient outcomes.
Masimo (NASDAQ: MASI) announces participation in the Piper Sandler Virtual Healthcare Conference on December 2, 2020, at 3:30 p.m. ET. The live presentation will be webcast on the Masimo website, with a replay available afterward. Masimo is recognized for its innovative medical monitoring technologies aimed at improving patient outcomes and reducing healthcare costs. Notably, Masimo SET® pulse oximetry is employed in over 100 million patients globally, with advancements enhancing its accuracy under various conditions.
Masimo (NASDAQ: MASI) announced a study published in the Ain-Shams Journal of Anesthesiology, highlighting the effectiveness of its PVi technology for assessing fluid responsiveness in mechanically ventilated patients. Conducted at Ain-Shams University, the study found PVi to be more reliable and continuous compared to dIVC, with significant results showing PVi's reliability (93.75% sensitivity) against an invasive method. These findings support PVi's potential in improving patient care in surgical ICU settings.
Masimo (NASDAQ: MASI) is set to present at the Stifel Virtual Healthcare Conference on November 17, 2020, at 2:40 p.m. Eastern Time. Live access to the presentation will be available via webcast on the Masimo website, with a replay offered afterward. Known for its advanced medical monitoring technologies, Masimo’s innovations, such as SET pulse oximetry, have significantly improved patient outcomes and reduced healthcare costs. The company’s products are used globally, impacting over 100 million patients and assisting healthcare professionals in critical care scenarios.
Masimo (NASDAQ: MASI) recently published a study in Blood Transfusion highlighting the advantages of utilizing its SpHb technology within a patient blood management (PBM) program for postoperative cancer patients. The study demonstrated a significant increase in transfusion appropriateness, rising from 38% to 79% with the implementation of SpHb monitoring. Additionally, the average number of red blood cell units transfused per patient declined from 1.8 to 1.3. The researchers emphasize that structured PBM programs can improve transfusion quality and quantity.
Masimo (NASDAQ: MASI) has announced that its wearable, tetherless vital signs monitor, Radius VSM™, has received CE marking and is being launched in select European markets. This versatile device can monitor various physiological parameters, including continuous pulse oximetry and noninvasive blood pressure. Radius VSM features a modular design suited for different patient needs and encourages mobility for faster recovery. It offers wireless communication with bedside monitors and EMR systems, enhancing patient care, especially during COVID-19. CEO Joe Kiani expressed excitement for its European rollout and future global availability.
Masimo (NASDAQ: MASI) reported strong Q3 2020 results, with total revenue reaching $278.1 million, a 21.4% increase from Q3 2019. Product revenue rose by 21.5%, while noninvasive technology shipments surged 150% year-over-year. GAAP net income was $49.4 million ($0.85 per share), compared to $49.1 million ($0.86) in 2019. The company updated its full-year 2020 guidance, projecting total revenue of $1,128.0 million and diluted EPS of $3.77. Masimo cited ongoing investments to address COVID-19 challenges as a key factor in its growth.
Masimo (NASDAQ: MASI) plans to release its third quarter 2020 financial results on October 27, 2020, after market close. CEO Joe Kiani and CFO Micah Young will host a conference call at 1:30 p.m. PT to discuss the results. Interested participants can register for the call through a provided link. Masimo is a leading medical technology company known for its innovative monitoring solutions that aim to enhance patient outcomes and reduce healthcare costs. The company has a significant presence in hospitals, particularly with its widely used Masimo SET pulse oximetry technology.
FAQ
What is the current stock price of Masimo Corporation (MASI)?
What is the market cap of Masimo Corporation (MASI)?
What is Masimo Corporation's main business?
How long has Masimo Corporation been in operation?
What are the key segments of Masimo's business?
What products does Masimo offer?
What makes Masimo's products unique?
Who uses Masimo's healthcare products?
What recent achievements has Masimo Corporation accomplished?
What is the financial status of Masimo Corporation?
What is Masimo's mission?